Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000081156 | SCV000113064 | pathogenic | not provided | 2012-10-30 | criteria provided, single submitter | clinical testing | |
Molecular Diagnostics Laboratory, |
RCV000760975 | SCV000890880 | pathogenic | Coffin-Lowry syndrome | 2016-08-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002514431 | SCV003555482 | likely pathogenic | Inborn genetic diseases | 2021-01-07 | criteria provided, single submitter | clinical testing | The c.632-1G>C intronic alteration results from of a G to C substitution one nucleotide before coding exon 9 of the RPS6KA3 gene. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. Based on data from the Genome Aggregation Database (gnomAD), the RPS6KA3 c.632-1G>C alteration was not observed, with coverage at this position. An alteration affecting the same nucleotide, c.632-1G>T, was reported in a patient with clinical features suggestive of Coffin-Lowry syndrome (Jacquot, 1998). The c.632-1G nucleotide is conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site. Based on the available evidence, this alteration is classified as likely pathogenic. |